6,9,10-Trihydroxy-7-megastigmen-3-oneCAS# 476682-97-0 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 476682-97-0 | SDF | Download SDF |
PubChem ID | 91885191 | Appearance | Powder |
Formula | C13H22O4 | M.Wt | 242.3 |
Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (4S,5R)-4-[(E)-3,4-dihydroxybut-1-enyl]-4-hydroxy-3,3,5-trimethylcyclohexan-1-one | ||
SMILES | CC1CC(=O)CC(C1(C=CC(CO)O)O)(C)C | ||
Standard InChIKey | NPIIJTPCHBVBJO-GKKQKQIKSA-N | ||
Standard InChI | InChI=1S/C13H22O4/c1-9-6-11(16)7-12(2,3)13(9,17)5-4-10(15)8-14/h4-5,9-10,14-15,17H,6-8H2,1-3H3/b5-4+/t9-,10?,13-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
6,9,10-Trihydroxy-7-megastigmen-3-one Dilution Calculator
6,9,10-Trihydroxy-7-megastigmen-3-one Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.1271 mL | 20.6356 mL | 41.2712 mL | 82.5423 mL | 103.1779 mL |
5 mM | 0.8254 mL | 4.1271 mL | 8.2542 mL | 16.5085 mL | 20.6356 mL |
10 mM | 0.4127 mL | 2.0636 mL | 4.1271 mL | 8.2542 mL | 10.3178 mL |
50 mM | 0.0825 mL | 0.4127 mL | 0.8254 mL | 1.6508 mL | 2.0636 mL |
100 mM | 0.0413 mL | 0.2064 mL | 0.4127 mL | 0.8254 mL | 1.0318 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lushanrubescensin H
Catalog No.:BCN3235
CAS No.:476640-22-9
- Eupaglehnin C
Catalog No.:BCN7118
CAS No.:476630-49-6
- VO-Ohpic trihydrate
Catalog No.:BCC2043
CAS No.:476310-60-8
- Boldine
Catalog No.:BCN5534
CAS No.:476-70-0
- Corydine
Catalog No.:BCN2669
CAS No.:476-69-7
- Ellagic acid
Catalog No.:BCN5533
CAS No.:476-66-4
- Chelidonine
Catalog No.:BCN2463
CAS No.:476-32-4
- Lycorine
Catalog No.:BCN2409
CAS No.:476-28-8
- Xylotriose
Catalog No.:BCN8428
CAS No.:47592-59-6
- Isotretinoin
Catalog No.:BCC2284
CAS No.:4759-48-2
- MCL 0020
Catalog No.:BCC6025
CAS No.:475498-26-1
- NVP-AEW541
Catalog No.:BCC1180
CAS No.:475489-16-8
- 3-(2-Benzothiazolylthio)propionic acid
Catalog No.:BCC8586
CAS No.:4767-00-4
- Boc-Tyr(2-Br-Z)-OH
Catalog No.:BCC3460
CAS No.:47689-67-8
- Lycorenine
Catalog No.:BCN2507
CAS No.:477-19-0
- Demecolcine
Catalog No.:BCC9223
CAS No.:477-30-5
- Samidin
Catalog No.:BCN6665
CAS No.:477-33-8
- Dehydrocostus lactone
Catalog No.:BCN5536
CAS No.:477-43-0
- Beta-Apopicropodophyllin
Catalog No.:BCC1388
CAS No.:477-52-1
- Podophyllotoxinone
Catalog No.:BCN8063
CAS No.:477-49-6
- Isotetrandrine
Catalog No.:BCN5538
CAS No.:477-57-6
- Isochondodendrine
Catalog No.:BCC9234
CAS No.:477-62-3
- Damnacanthal
Catalog No.:BCN5539
CAS No.:477-84-9
- Obtusifolin
Catalog No.:BCN2537
CAS No.:477-85-0
ZnBr2-Mediated oxidative spiro-bromocyclization of propiolamide for the synthesis of 3-bromo-1-azaspiro[4.5]deca-3,6,9-triene-2,8-dione.[Pubmed:28379277]
Org Biomol Chem. 2017 Apr 18;15(16):3485-3490.
ZnBr2-Mediated oxidative spiro-bromocyclization of N-arylpropiolamide has been described herein for the synthesis of 3-bromo-1-azaspiro[4.5]deca-3,6,9-triene-2,8-dione with high efficiency. One equivalent of water was introduced into the final product. The reaction efficiently proceeded at room temperature, and an excellent tolerance of functional groups was demonstrated. Under standard conditions, 3-bromo-1-oxaspiro[4.5]deca-3,6,9-triene-2,8-dione and 3-bromo-1-azaspiro[4.5]deca-3,6,9-trien-8-one were synthesized.
Fundamental Motor Skill Proficiency of 6- to 9-Year-Old Singaporean Children.[Pubmed:28376671]
Percept Mot Skills. 2017 Jun;124(3):584-600.
Fundamental movement proficiency (FMS) is most successfully acquired during early school years. This cross-sectional study assessed FMS proficiency in Singaporean children at the start of and following 2.5 years of primary school physical education (PE). Participants were 244 children from Primary 1 and 3 levels. Fundamental movement skills (FMS) were assessed with the Test of Gross Motor Development-Second Edition (TGMD-2) that includes locomotor (LOCO) and object control (OC) subtests. Most children were rated "average" and "below average" for LOCO skills but "poor" and "below average" for OC skills without significant gender differences on either subtest or overall FMS proficiency and without FMS mastery. These young Singaporean children failed to exhibit age-appropriate FMS proficiency despite early PE exposure, and they demonstrated lags in FMS compared with the TGMD-2 U.S. normative sample. We discuss implications for sports competence perception, difficulty in coping with later movement learning expectations and reduced later motivation to participate in PE and play. We also discuss implications for preschool and lower primary school PE curricula with a particular focus on both OC skills and LOCO skills requiring muscular fitness like hopping and jumping.
Foxn1 and Mmp-9 expression in intact skin and during excisional wound repair in young, adult, and old C57Bl/6 mice.[Pubmed:28371152]
Wound Repair Regen. 2017 Apr;25(2):248-259.
The transcription factor Foxn1 is essential for skin development. Our previous studies performed on young C57BL/6J mice model showed that Foxn1 acts as regulator of the skin wound healing process. The present study extended our initial research regarding the expression and potential role of Foxn1 in the intact and wounded skin as a function of animal age and stage of the wound healing process. We analyzed Foxn1 and Mmp-9 expression in the intact and postinjured skin of young, adult, and old C57BL/6J and transgenic Foxn1::Egfp mice. The similar levels of epidermal Foxn1 mRNA expression were detected in young and adult C57BL/6J mice and higher levels in old animals. Postinjured skin tissues displayed a gradual decrease of Foxn1 mRNA expression at Days 1, 5, and 7 after injury. Foxn1-eGFP positive cells were abundant at wound margin and in re-epithelialized epidermis at postwounded Days 1, 5, and 7 and colocalized with E-cadherin and Mmp-9. Postwounded skin at Days 14-36 displayed Foxn1-eGFP cells in the epidermis and in the dermal part of the skin (papillary dermis). A subset of Foxn1-eGFP positive cells in the papillary dermis expressed the myofibroblast marker alphaSMA. Flow cytometric analysis of cells isolated from postwounded (Day 7) skin tissues showed a significant increase in the percentage of Foxn1-eGFP positive cells with phenotype of double positivity for E-cadherin/N-cadherin (epithelial/mesenchymal markers). Collectively, these data identify the transcription factor Foxn1 as a potential key epidermal regulator modifying both epidermal and dermal healing processes after cutaneous wounding.
Crystal structure of 5,6-bis(9H-carbazol-9-yl)benzo[c][1,2,5]thiadiazole: distortion from a hypothetical higher-symmetry structure.[Pubmed:28378715]
Acta Crystallogr C Struct Chem. 2017 Apr 1;73(Pt 4):319-324.
Nucleophilic substitution of F atoms in 5,6-difluorobenzo[c][1,2,5]thiadiazole (DFBT) for carbazole could be potentially interesting as a novel way of synthesizing building blocks for new conjugated materials for applications in organic chemistry. The crystal structures of 5,6-bis(9H-carbazol-9-yl)benzo[c][1,2,5]thiadiazole (DCBT), C30H18N4S, and its hydrate, C30H18N4S.0.125H2O, were investigated using single-crystal X-ray analysis. The hydrate contains two symmetry-independent DCBT molecules. The dihedral angles between the plane of the central benzothiadiazole fragment and that of the carbazole units vary between 50.8 and 69.9 degrees , indicating conformational flexibility of the DCBT molecule in the crystals, which is consistent with quantum chemical calculations. The analysis of the crystal packing of DCBT revealed that the experimental triclinic structure could be described as a distortion from a hypothetical higher-symmetry monoclinic structure. The quantum chemical calculations of two possible monoclinic structures, which are related to the experimental structure by a shifting of molecular layers, showed that the proposed structures are higher in energy by 5.4 and 10.1 kcal mol(-1). This energy increase is caused by less dense crystal packings of the symmetric structures, which results in a decrease of the number of intermolecular interactions.